Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).

View Full Paper
Ask AI
Bookmark
Share

Authors

EMErin MulveySNSarah NazirZGZahra Grant

Discussion

Loading...

Member takes

Overview

Interim data shows venetoclax and obinutuzumab improves complete response and minimal residual disease in CLL/SLL patients.

Key Points

  • To assess the efficacy and safety of initial therapy combining zanubrutinib and venetoclax with obinutuzumab for CLL/SLL patients.
  • Initial treatment with zanubrutinib and venetoclax, followed by obinutuzumab if minimal residual disease was detected.
  • Evaluated patients based on International Workshop on CLL 2018 guidelines.
  • Cohort treated for a median follow-up of 13 months with assessment of disease status and adverse events.
  • 97% overall response rate in evaluable patients.
  • 35% achieved complete response after 16 cycles.
  • High rates of undetectable minimal residual disease were observed after consolidation with obinutuzumab.

Cite This Study

Mulvey et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d869https://doi.org/10.1182/blood-2025-3886
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study2025 · 1 citations
  2. 2Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia2025 · 3 citations
  3. 3Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-1012025 · 1 citations
  4. 4A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study2025
  5. 5Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs2026